dc.contributor.author |
Musallam K.M. |
dc.contributor.author |
Cappellini M.D. |
dc.contributor.author |
Taher A.T. |
dc.contributor.editor |
|
dc.date |
Jun-2013 |
dc.date.accessioned |
2017-10-05T15:38:18Z |
dc.date.available |
2017-10-05T15:38:18Z |
dc.date.issued |
2013 |
dc.identifier |
10.1016/j.bcmd.2013.01.015 |
dc.identifier.isbn |
|
dc.identifier.issn |
10799796 |
dc.identifier.uri |
http://hdl.handle.net/10938/16265 |
dc.description.abstract |
Iron overload may still occur in transfusion-independent patients with β-thalassemia intermedia due to increased intestinal iron absorption. In this study, we evaluated the association between iron overload, using a liver iron concentration threshold of therapeutic significance (≥. 5. mg-g), and morbidity in 168 chelation naive patients with β-thalassemia intermedia. We demonstrated that patients with a liver iron concentration ≥. 5. mg-g have a significantly higher prevalence of several serious vascular and endocrine-bone morbidities than do patients with . 5. mg-g, and we established absolute morbidity risk values differentiating both groups. We also demonstrated that the association between iron overload and morbidity in such patients is independent of the effects of advancing age and disease severity. These findings suggest that treating iron burden in β-thalassemia intermedia may be associated with reduction in serious morbidity risk. © 2013 Elsevier Inc. |
dc.format.extent |
|
dc.format.extent |
Pages: (35-38) |
dc.language |
English |
dc.publisher |
SAN DIEGO |
dc.relation.ispartof |
Publication Name: Blood Cells, Molecules, and Diseases; Publication Year: 2013; Volume: 51; no. 1; Pages: (35-38); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Evaluation of the 5mg-g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia |
dc.type |
Article |
dc.contributor.affiliation |
Musallam, K.M., Department of Medicine and Medical Specialties, IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, University of Milan, Milan, Italy, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Cappellini, M.D., Department of Medicine and Medical Specialties, IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, University of Milan, Milan, Italy |
dc.contributor.affiliation |
Taher, A.T., Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon, Chronic Care Center, Hazmieh, Lebanon |
dc.contributor.authorAddress |
Taher, A.T.; Department of Internal Medicine, American University of Beirut Medical Center, P.O. Box: 11-0236, Riad El-Solh 1107 2020, Beirut, Lebanon; email: ataher@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; |
dc.contributor.authorDepartment |
Internal Medicine |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
ataher@aub.edu.lb |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Musallam, KM |
dc.contributor.authorInitials |
Cappellini, MD |
dc.contributor.authorInitials |
Taher, AT |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Taher, AT (reprint author), Amer Univ Beirut, Med Ctr, Dept Internal Med, POB 11-0236,Riad El Solh 1107, Beirut 2020, Lebanon. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Belhoul KM, 2012, ANN HEMATOL, V91, P1107, DOI 10.1007-s00277-012-1412-7; Haidar R, 2011, BONE, V48, P425, DOI 10.1016-j.bone.2010.10.173; Kell DB, 2009, BMC MED GENOMICS, V2, DOI 10.1186-1755-8794-2-2; Musallam KM, 2011, HEMOGLOBIN, V35, P503, DOI 10.3109-03630269.2011.605499; Musallam KM, 2012, BLOOD CELL MOL DIS, V49, P136, DOI 10.1016-j.bcmd.2012.06.001; Musallam KM, 2011, HAEMATOL-HEMATOL J, V96, P1605, DOI 10.3324-haematol.2011.047852; Musallam KM, 2012, BLOOD REV, V26, pS16, DOI 10.1016-S0268-960X(12)70006-1; Musallam KM, 2012, THROMB RES, V130, P695, DOI 10.1016-j.thromres.2012.07.013; Pootrakul P, 2003, BRIT J HAEMATOL, V122, P305, DOI 10.1046-j.1365-2141.2003.04412.x; Rivella S, 2012, BLOOD REV, V26, pS12, DOI 10.1016-S0268-960X(12)70005-X; St Pierre TG, 2005, BLOOD, V105, P855, DOI 10.1182-blood-2004-01-0177; Taher A, 2008, HAEMATOL-HEMATOL J, V93, P1584, DOI 10.3324-haematol.13098; Taher AT, 2012, BLOOD, V120, P970, DOI 10.1182-blood-2012-02-412692; Taher AT, 2010, BLOOD, V115, P1886, DOI 10.1182-blood-2009-09-243154; Wood JC, 2005, BLOOD, V106, P1460, DOI 10.1182-blood-2004-10-3982 |
dc.description.citedCount |
5 |
dc.description.citedTotWOSCount |
10 |
dc.description.citedWOSCount |
10 |
dc.format.extentCount |
4 |
dc.identifier.articleNo |
|
dc.identifier.coden |
BCMDF |
dc.identifier.pubmedID |
23425967 |
dc.identifier.scopusID |
84877128415 |
dc.identifier.url |
|
dc.publisher.address |
525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Blood Cells Mol. Dis. |
dc.relation.ispartOfIssue |
1 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Blood Cells, Molecules, and Diseases |
dc.relation.ispartofPubTitleAbbr |
Blood Cells Mol. Dis. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
51 |
dc.source.ID |
WOS:000330206500008 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
Iron overload |
dc.subject.otherAuthKeyword |
Liver iron concentration |
dc.subject.otherAuthKeyword |
Morbidity |
dc.subject.otherAuthKeyword |
Thalassemia intermedia |
dc.subject.otherChemCAS |
Iron, E1UOL152H7 |
dc.subject.otherIndex |
age |
dc.subject.otherIndex |
aged |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
beta thalassemia |
dc.subject.otherIndex |
bone disease |
dc.subject.otherIndex |
child |
dc.subject.otherIndex |
cross-sectional study |
dc.subject.otherIndex |
disease severity |
dc.subject.otherIndex |
endocrine disease |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
hypogonadism |
dc.subject.otherIndex |
hypothyroidism |
dc.subject.otherIndex |
iron chelation |
dc.subject.otherIndex |
iron liver level |
dc.subject.otherIndex |
iron overload |
dc.subject.otherIndex |
liver level |
dc.subject.otherIndex |
morbidity |
dc.subject.otherIndex |
osteoporosis |
dc.subject.otherIndex |
prevalence |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
pulmonary hypertension |
dc.subject.otherIndex |
risk reduction |
dc.subject.otherIndex |
school child |
dc.subject.otherIndex |
thrombosis |
dc.subject.otherIndex |
vascular disease |
dc.subject.otherIndex |
Adolescent |
dc.subject.otherIndex |
Adult |
dc.subject.otherIndex |
Aged |
dc.subject.otherIndex |
beta-Thalassemia |
dc.subject.otherIndex |
Child |
dc.subject.otherIndex |
Cross-Sectional Studies |
dc.subject.otherIndex |
Female |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Iron |
dc.subject.otherIndex |
Iron Overload |
dc.subject.otherIndex |
Liver |
dc.subject.otherIndex |
Male |
dc.subject.otherIndex |
Middle Aged |
dc.subject.otherIndex |
Morbidity |
dc.subject.otherIndex |
Young Adult |
dc.subject.otherKeywordPlus |
TRANSFUSION-DEPENDENT THALASSEMIA |
dc.subject.otherKeywordPlus |
SERUM FERRITIN LEVELS |
dc.subject.otherKeywordPlus |
MAGNETIC-RESONANCE |
dc.subject.otherKeywordPlus |
CHELATION |
dc.subject.otherKeywordPlus |
OVERLOAD |
dc.subject.otherKeywordPlus |
R2 |
dc.subject.otherWOS |
Hematology |